Illumina (NASDAQ:ILMN) Director Keith Meister Sells 220,000 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 220,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $152.27, for a total transaction of $33,499,400.00. Following the sale, the director directly owned 3,280,048 shares of the company’s stock, valued at approximately $499,452,908.96. This represents a 6.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Illumina Price Performance

NASDAQ ILMN opened at $164.40 on Tuesday. Illumina, Inc. has a 52 week low of $78.79 and a 52 week high of $165.97. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock has a market cap of $24.87 billion, a price-to-earnings ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50. The company has a 50-day moving average price of $134.48 and a two-hundred day moving average price of $132.39.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.97 EPS. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Citigroup increased their target price on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Piper Sandler reduced their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective on the stock. Finally, Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and a consensus target price of $138.38.

Hedge Funds Weigh In On Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Illumina by 7.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the period. HighPoint Advisor Group LLC boosted its position in Illumina by 3.7% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after buying an additional 85 shares in the last quarter. Toronto Dominion Bank boosted its position in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after buying an additional 92 shares in the last quarter. Finally, Assetmark Inc. increased its position in Illumina by 10.2% in the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after acquiring an additional 96 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.